Septerna (SEPN) risk factors
Item 1A of every Septerna, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors97 risks7 new8 dropped16 reworded
Septerna added critical disclosures regarding U.S. government shutdowns affecting the FDA and SEC, reliance on Chinese suppliers like WuXi, and potential patent infringement risks. The company noted specific exposures including hypoparathyroidism treatments and collaborations with Novo.
Filed Mar 09, 2026 - FY2024 10-K risk factors98 risks
Septerna is a clinical-stage biotechnology company with 75 employees, focusing on endocrinology, immunology, and neurology programs like SEP-786. The company faces high regulatory hurdles, intense competition, and relies entirely on external funding and partnerships since generating no product revenue.
Filed Mar 27, 2025